Quantcast

Latest Ataluren Stories

2014-07-09 16:28:13

-French ATU Cohort and Other Named Patient Programs Authorized - SOUTH PLAINFIELD, N.J., July 9, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna(TM) (ataluren) available to patients before commercial availability in certain countries. Where mechanisms exist and in accordance with local regulations, PTC will make Translarna available to nonsense...

2014-06-30 08:30:32

SOUTH PLAINFIELD, N.J., June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a global confirmatory Phase 3 clinical trial of Translarna(TM) (ataluren), an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). Nonsense mutations within cystic fibrosis are categorized as Class I mutations, a severe form of CF that results in little or no production of the CFTR protein. The Phase 3 confirmatory trial is...

2014-06-30 08:30:29

SOUTH PLAINFIELD, N.J., June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it is the recipient of Parent Project Muscular Dystrophy's (PPMD) "Path to Progress" award, honoring PTC's 16 years of commitment to bring the first-ever therapy for the underlying cause of the disorder to patients with Duchenne muscular dystrophy (DMD). The award was presented at PPMD's Annual Connect Conference in Chicago, Illinois....

2014-06-24 12:27:59

CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process BETHESDA, Md., June 24, 2014 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation applauds the successful results of Phase 3 studies of ivacaftor (Kalydeco(TM)) in combination with lumacaftor (VX-809) for people with two copies of the F508del mutation of cystic fibrosis (CF). The results showed significant improvements in lung function and other key measures of the disease,...

2014-05-26 12:21:59

LONDON, May 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growthhttp://www.reportbuyer.com/pharma_healthcare/diseases/cystic_fibrosis_therapeutics_major_developed_markets_2019_cftr_modulators_initiate_drive_towards_personalized_treatment_market_growth.htmlCystic Fibrosis Therapeutics in Major Developed Markets...

2014-05-23 08:23:53

- The first treatment for the underlying cause of Duchenne muscular dystrophy - SOUTH PLAINFIELD, N.J., May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of Translarna(TM) (ataluren) for the treatment...

2014-05-23 08:23:51

Conference Call on Friday, May 23, 2014 at 8:30 am ET SOUTH PLAINFIELD, N.J., May 23, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will provide an update on the re-examination of its marketing authorization application to the European Medicines Agency (EMA) for conditional marketing authorization of Translarna(TM) (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy. PTC will hold a conference call at 8:30 am ET...

2014-05-16 08:26:28

- Data Demonstrate Positive Trends in Lung Function and Pulmonary Exacerbations - SOUTH PLAINFIELD, N.J., May 16, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the results of a Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) were published in Lancet Respiratory Medicine. The results demonstrated positive trends in both the primary endpoint, lung function as measured by relative change in % predicted FEV(1) (forced...

2014-03-06 16:27:15

-Conference Call Today at 4:30 pm ET- SOUTH PLAINFIELD, N.J., March 6, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. http://photos.prnewswire.com/prnvar/20010919/PTCLOGO "2013 was a landmark year for PTC with significant accomplishments achieved across the organization. Our private financing early in the year combined with a very successful IPO...

2014-02-25 08:32:07

SOUTH PLAINFIELD, N.J., Feb. 25, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Guido Schopen, M.D. to General Manager and Head of Medical Affairs for Europe. Dr. Schopen will be responsible for European commercial operations, reporting to Mark Rothera, Chief Commercial Officer of PTC. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) "We are delighted to welcome Dr. Schopen to our team where he will play a key leadership role...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related